肯尼亚青少年女性单剂HPV疫苗效力研究(KEN SHE):随机对照试验方案
KEN SHE是一项在肯尼亚15-20岁女性中开展的个体随机对照试验,比较立即接种单剂二价或九价HPV疫苗与延迟接种的效力,主要结局为18个月和36个月持续疫苗型HPV感染,并设免疫桥接、记忆B细胞及成本效果分析。
要点
- 单剂HPV疫苗方案可能缓解疫苗供应与物流限制。
- 主要比较立即单剂二价或九价HPV疫苗与延迟接种的效力。
- 次要目标包括免疫桥接、记忆B细胞反应和成本效果评估。
核心结论
- 该试验将评估非洲单剂HPV疫苗效力,有望指导公共卫生政策并提高HPV疫苗覆盖率。
研究设计与样本
- 个体随机对照试验,肯尼亚15-20岁女性随机分为立即二价HPV疫苗加延迟脑膜炎球菌疫苗组、立即九价HPV疫苗加延迟脑膜炎球菌疫苗组、立即脑膜炎球菌疫苗加延迟HPV疫苗组,随访36个月。
关键数值与推荐
- 主要结局为18个月时持续疫苗型HPV感染,36个月时为最终持久性结局。
- 次要目标包括与坦桑尼亚DoRIS研究(NCT02834637)9-14岁女孩及青少年抗体滴度的非劣效性评价。
- 次要目标包括评估36个月和37个月时的记忆B细胞免疫应答。
- 次要目标包括利用试验结果和卫生经济模型估计成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HPV infection is the primary cause of cervical cancer, a leading cause of cancer among women in Kenya and many sub-Saharan African countries. High coverage of HPV vaccination is a World Health Organization priority to eliminate cervical cancer globally, but vaccine supply and logistics limit widespread implementation of the current two or three dose HPV vaccine schedule. METHODS: We are conducting an individual randomized controlled trial to evaluate whether a single dose of the bivalent (HPV 16/18) or nonavalent (HPV 16/18/31/33/45/52/58/6/11) HPV vaccine prevents persistent HPV infection, a surrogate marker for precancerous lesions and cervical cancer. The primary objective is to compare the efficacy of immediate, single-dose bivalent or nonavalent vaccination with delayed HPV vaccination. Kenyan women age 15-20 years old are randomized to immediate bivalent HPV and delayed meningococcal vaccine (group 1), immediate nonavalent HPV vaccine and delayed meningococcal vaccine (group 2), or immediate meningococcal vaccine and delayed HPV vaccine (group 3) with 36 months of follow-up. The primary outcome is persistent vaccine-type HPV infection by month 18 and by month 36 for the final durability outcome. The secondary objectives include to (1) evaluate non-inferiority of antibody titers among girls and adolescents (age 9 to 14 years) from another Tanzanian study, the DoRIS Study (NCT02834637), compared to KEN SHE Study participants; (2) assess the memory B cell immune response at months 36 and 37; and (3) estimate cost-effectiveness using the trial results and health economic models. DISCUSSION: This study will evaluate single-dose HPV vaccine efficacy in Africa and has the potential to guide public health policy and increase HPV vaccine coverage. The secondary aims will assess generalizability of the trial results by evaluating immunobridging from younger ages, durability of the immune response, and the long-term health benefits and cost of single-dose HPV vaccine delivery. TRIAL REGISTRATION: ClinicalTrials.gov NCT03675256 . Registered on September 18, 2018.
引用
- Barnabas RV, Brown ER, Onono M, et al. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. Trials. 2021. PMID: 34579786. doi:10.1186/s13063-021-05608-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。